RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345

Benzinga · 3d ago
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $350 to $345.